$0.98-0.02 (-2.33%)
MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. in the Healthcare sector is trading at $0.98. The stock is currently near its 52-week low of $0.90, remaining 24.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican righ...
The Coach owner said it is trimming the time it takes to analyze data through its newly patented AI technology.
Key Takeaways; Cannabis Sector Aurora Cannabis Announced Refocused Strategy as Global Medical Sales Hit Record High in 2026 Third Quarter Canopy Growth Reported Mixed Results in its Fiscal Third Quarter of 2026 Cronos Group Launched Premium Lord Jones Brand in Israel in Global Expansion Push Key Takeaways; Psychedelic Sector Clearmind Announced the Inclusion of its […]
Health care stocks fell late Thursday afternoon with the NYSE Health Care Index down 0.2% and the He
FiEE (MINM) shares were up 37% in recent Thursday premarket activity, after the company said Wednesd
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) on Monday revealed new animal study results from SKNY-1, a next-generation oral therapeutic. The company says the findings further support the advancement of SKNY-1 toward Investigational New Drug (IND) enabling studies. With obesity and smoking representing two of the leading causes of preventable death and a combined global market opportunity exceeding $200 billion, MIRA intends to prioritize SKNY-1 as a potential cornerstone asset pending the completio